



# Preferred Drug List

## NEW DRUG REVIEW

**Proprietary Name:** Sutent®

**Common Name:** Sunitinib

**PDL Category:** Antineoplastics - Misc.

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Hydroxyurea Cap	Recommended
Matulane	Recommended

### Summary

**Indications and Usage:** Treatment of gastrointestinal stromal tumor after disease progression on, or intolerance to imatinib mesylate; treatment of advanced renal cell carcinoma

**Dosage Forms:** Capsules; 12.5mg, 25mg, and 50mg

**Recommended Dosage:** One 50mg capsule once daily, on a schedule of four weeks on treatment followed by two weeks off.

**Common Adverse Drug Reactions:** Hypothyroidism, anemia, neutropenia, left ventricular dysfunction.

**Contraindications:** Contraindicated in patients with hypersensitivity to sunitinib malate, or to any other component of the medication

**Manufacturer:** Pfizer

**Analysis:** When studied in gastrointestinal stromal tumor, Sutent® showed a significant clinical benefit in early data analysis. Sutent® also has shown the ability to reduce the size of tumors in patients with advanced renal cell carcinoma where tumors did not adequately respond to cytokine-based therapy. Due to the dual FDA indications, this medication is a cost effective choice for management of these diagnoses.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input checked="" type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	